The Chk1 inhibitor prexasertib (12 mg/kg, BID, 2/7 days) elicited a immune-mediated anti-tumor response in both in vitro and in vivo in Small Cell Lung Cancer (SCLC) models. This evidence concerns the gene CHEK1 and small cell lung carcinoma.